Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A RANDOMIZED PHASE-II TRIAL OF AMONAFIDE OR TRIMETREXATE IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER - A TRIAL OF THE NORTH-CENTRAL-CANCER-TREATMENT-GROUP
Autore:
GESME DH; JETT JR; SCHREFFLER DD; SU JQ; MAILLIARD JA; FOLEY JF; KROOK JE; MAKSYMIUK AW; HATFIELD AK; EBBERT LP; PFEIFLE DM; MORTON RF; TSCHETTER LK; SCHAEFER PL;
Indirizzi:
MAYO CLIN & MAYO FDN,DIV MED ONCOL,200 1ST ST ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,DIV MED ONCOL,200 1ST ST ROCHESTER MN 55905 CEDAR RAPIDS ONCOL PROJECT CCOP CEDAR RAPIDS IA 00000 BILLINGS CLIN BILLINGS MT 00000 MAYO CLIN & MAYO FDN,CANC STAT UNIT ROCHESTER MN 55905 UNIV NEBRASKA,MED CTR OMAHA NE 68105 NEBRASKA ONCOL GRP OMAHA NE 00000 CREIGHTON UNIV,NEBRASKA ONCOL GRP OMAHA NE 68178 DULUTH CCOP DULUTH MN 00000 SASKATCHEWAN CANC FDN,SASKATOON CANC CLIN SASKATOON SK CANADA ALLAN BLAIR MEM CLIN REGINA SK CANADA CARLE CANC CTR CCOP URBANA IL 00000 RAPID CITY REG ONCOL GRP CCOP RAPID CITY SD 00000 QUAIN & RAMSTAD CLIN BISMARCK ND 00000 IOWA ONCOL RES ASSOC CCOP DES MOINES IA 00000 SIOUX COMMUNITY CANC CONSORTIUM CCOP SIOUX FALLS SD 00000 TOLEDO CCOP TOLEDO OH 00000
Titolo Testata:
Cancer
fascicolo: 9, volume: 71, anno: 1993,
pagine: 2723 - 2726
SICI:
0008-543X(1993)71:9<2723:ARPTOA>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
STAGE-III; CHEMOTHERAPY;
Keywords:
AMONAFIDE; TRIMETREXATE; NONSMALL CELL LUNG CANCER; CHEMOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
D.H. Gesme et al., "A RANDOMIZED PHASE-II TRIAL OF AMONAFIDE OR TRIMETREXATE IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER - A TRIAL OF THE NORTH-CENTRAL-CANCER-TREATMENT-GROUP", Cancer, 71(9), 1993, pp. 2723-2726

Abstract

Background. In an effort to identify new active chemotherapeutic agents against non-small cell lung cancer (NSCLC), the authors conducted arandomized Phase II trial to evaluate the efficacy of amonafide or trimetrexate in patients with Stage IV disease. Methods. This was a multicenter Cooperative Oncology Group trial. All patients had advanced NSCLC and were previously untreated with chemotherapy. Patients were randomized to treatment after enrollment. Amonafide was administered as a24-hour continuous infusion (1600 mg/m2) every 21 days. Trimetrexate (150 mg/m2) was administered intravenously over 30 minutes every 2 weeks. The primary endpoints of the study were clinical response and toxic effects. All patients were observed for survival. Results. Thirty-five patients received amonafide and were assessable. There were no complete responses and two partial responses (6%). Thirty-seven patients were treated with trimetrexate. There were no complete responses and five (14%) partial responses. Myelosuppression was the primary toxic effect observed with amonafide treatment. Trimetrexate was associated infrequently with clinically significant side effects. Conclusions. Amonafide is inactive against NSCLC, and no additional studies with this agent are planned. Trimetrexate has some activity against NSCLC, but itsrole in the future therapy of this disease is questionable.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 05:39:02